{"id": "179467", "url": "https://fevir.net/resources/Composition/179467", "date": "2025-09-13T19:05:42.542Z", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation"], "versionId": "20", "lastUpdated": "2025-09-13T19:05:42.542Z"}, "type": {"coding": [{"code": "Recommendation", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Recommendation"}]}, "title": "Recommendation: ADA Obesity Management Recommendation 8.17", "author": [{"type": "Practitioner", "display": "Brian S. Alper"}], "status": "final", "custodian": {"type": "Organization", "display": "Computable Publishing LLC", "reference": "Organization/118079"}, "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-description", "valueMarkdown": "Example of Recommendation Profile of Composition Resource."}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "relatesTo": [{"type": "cite-as", "targetMarkdown": "Recommendation: ADA Obesity Management Recommendation 8.17 [Database Entry: FHIR Composition Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179467. Revised 2025-09-13. Available at: https://fevir.net/resources/Composition/179467. Computable resource at: https://fevir.net/resources/Composition/179467#json."}, {"type": "derived-from", "targetReference": {"type": "Citation", "display": "JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes", "reference": "Citation/32137"}}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "179467", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Composition", "section": [{"code": {"text": "overallSummary", "coding": [{"code": "recommendation-statement", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Recommendation Statement"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">8.17 Metabolic surgery may be considered as an option to treat type 2 diabetes in adults with BMI 30.0\u201334.9 kg/m2 (27.5\u201332.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. A</div>", "status": "generated"}, "title": "Recommendation Statement"}, {"code": {"text": "overallRatings", "coding": [{"code": "ratings", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Ratings"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A</div>", "status": "generated"}, "entry": [{"type": "ArtifactAssessment", "reference": "ArtifactAssessment/179515"}], "title": "Recommendation Ratings"}, {"code": {"text": "population", "coding": [{"code": "population", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Population"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Inclusion Criteria: [[1]] Adults. [[2]] Diagnosed with type 2 diabetes. [[3]] Body Mass Index (BMI) \u2265 30.0 kg/m2 and \u2264 34.9 kg/m2 (BMI 27.5-32.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. [[4]] Screened surgical candidates.</div>", "status": "generated"}, "entry": [{"type": "Group", "display": "RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)", "reference": "Group/179511"}], "title": "Population"}, {"code": {"text": "action", "coding": [{"code": "action", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Action"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Metabolic surgery may be considered.</div>", "status": "generated"}, "entry": [{"type": "PlanDefinition", "display": "PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17", "reference": "PlanDefinition/179554"}], "title": "Action"}, {"code": {"text": "oppositeAction", "coding": [{"code": "opposite-action", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Opposite Action"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "title": "Opposite Action", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "introduction", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Introduction"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>", "status": "empty"}, "title": "Introduction Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "justification", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Justification"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><strong>Title: </strong>Justification for Recommendation: ADA Obesity Management Recommendation 8.17</p> &#160; <p><strong>Justification for Recommendation: </strong>Recommendation: ADA Obesity Management Recommendation 8.17</p> &#160; <table><tbody><tr><th>Concept</th><th>Summary</th><th>Rating</th></tr><tr><td>Recommendation Specification (coded as: RJCS-content0 from https://fevir.net/resources/CodeSystem/27834); Recommendation Specification (coded as: recommendation-specification from https://fevir.net/resources/CodeSystem/179423)</td><td>8.17 Metabolic surgery may be considered as an option to treat type 2 diabetes in adults with BMI 30.0\u201334.9 kg/m2 (27.5\u201332.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. A</td><td>undefined</td></tr><tr><td>Rating System (coded as: rating-system from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>ADA Level of Evidence</td></tr><tr><td>Strength of Recommendation (coded as: RJCS-1000 from https://fevir.net/resources/CodeSystem/27834); Strength of Recommendation (coded as: strength-of-recommendation from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Direction of Recommendation (coded as: RJCS-1014 from https://fevir.net/resources/CodeSystem/27834); Direction of Recommendation (coded as: direction-of-recommendation from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>Favors intervention (coded as: RJCS-2021 from https://fevir.net/resources/CodeSystem/27834)</td></tr><tr><td>Ratings (coded as: ratings from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>A</td></tr><tr><td>Evidence (coded as: RJCS-content1 from https://fevir.net/resources/CodeSystem/27834); Evidence (coded as: evidence from https://fevir.net/resources/CodeSystem/179423)</td><td>ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</td><td>undefined</td></tr><tr><td>Summary of Findings (coded as: summary-of-findings from https://fevir.net/resources/CodeSystem/179423)</td><td>ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</td><td>undefined</td></tr><tr><td>Desirable Effects (coded as: RJCS-1004 from https://fevir.net/resources/CodeSystem/27834); Desirable Effects (coded as: desirable-effects from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Undesirable Effects (coded as: RJCS-1005 from https://fevir.net/resources/CodeSystem/27834); Undesirable Effects (coded as: undesirable-effects from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Discussion (coded as: discussion from https://fevir.net/resources/CodeSystem/179423)</td><td>A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions. &#160; In extended follow-up of obese adults with type 2 diabetes randomized to adding gastric bypass compared with lifestyle and intensive medical management alone, there remained a significantly better composite triple end point in the surgical group at 5 years. However, because the effect size diminished over 5 years, further follow-up is needed to understand the durability of the improvement.</td><td>undefined</td></tr><tr><td>Net Effect (coded as: RJCS-1007 from https://fevir.net/resources/CodeSystem/27834); Net Effect (coded as: net-effect from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Values/Preferences (coded as: RJCS-1006 from https://fevir.net/resources/CodeSystem/27834); Preferences (coded as: preferences from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Discussion (coded as: discussion from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Judgments (coded as: RJCS-content2 from https://fevir.net/resources/CodeSystem/27834); Judgments (coded as: judgments from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Justification (coded as: justification from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Problem Importance (coded as: RJCS-1003 from https://fevir.net/resources/CodeSystem/27834); Problem Importance (coded as: problem-importance from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Resources/Costs (coded as: RJCS-1008 from https://fevir.net/resources/CodeSystem/27834); Costs (coded as: costs from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Cost-effectiveness (coded as: RJCS-1009 from https://fevir.net/resources/CodeSystem/27834); Cost-effectiveness (coded as: cost-effectiveness from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Equity (coded as: RJCS-1010 from https://fevir.net/resources/CodeSystem/27834); Equity (coded as: equity from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Acceptability (coded as: RJCS-1011 from https://fevir.net/resources/CodeSystem/27834); Acceptability (coded as: acceptability from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Feasibility (coded as: RJCS-1012 from https://fevir.net/resources/CodeSystem/27834); Feasibility (coded as: feasibility from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Competing Interests (coded as: RJCS-1002 from https://fevir.net/resources/CodeSystem/27834); Competing Interests (coded as: competing-interests from https://fevir.net/resources/CodeSystem/179423)</td><td>All members of the PPC are required to disclose potential conflicts of interest with industry and other relevant organizations. These disclosures are discussed at the outset of each Standards of Care revision meeting. Members of the committee, their employers, and their disclosed conflicts of interest are listed in 'Disclosures: Standards of Medical Care in Diabetes\u20142021' (https://doi.org/10.2337/dc21-SPPC). The ADA funds development of the Standards of Care out of its general revenues and does not use industry support for this purpose. NOTE: The disclosed conflicts of interest was not found at the suggested URL</td><td>undefined</td></tr></tbody></table> &#160; </div>", "status": "additional"}, "entry": [{"type": "ArtifactAssessment", "display": "Justification for Recommendation: ADA Obesity Management Recommendation 8.17", "reference": "ArtifactAssessment/179515"}], "title": "Justification"}, {"code": {"coding": [{"code": "considerations", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Considerations"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "title": "Considerations", "section": [{"code": {"text": "overallConsiderationsSummary", "coding": [{"code": "summary", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary"}]}, "title": "Overall Considerations Summary", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"text": "subgroupConsiderationsSummary", "coding": [{"code": "subgroup-considerations", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Subgroup Considerations"}]}, "title": "Subgroup Considerations Summary", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"text": "implementationConsiderationsSummary", "coding": [{"code": "implementation-considerations", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Implementation Considerations"}]}, "title": "Implementation Considerations Summary", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"text": "monitoringConsiderationsSummary", "coding": [{"code": "monitoring-considerations", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Monitoring Considerations"}]}, "title": "Monitoring Considerations Summary", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"text": "competingInterestsSummary", "coding": [{"code": "competing-interests", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Competing Interests"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All members of the PPC are required to disclose potential conflicts of interest with industry and other relevant organizations. These disclosures are discussed at the outset of each Standards of Care revision meeting. Members of the committee, their employers, and their disclosed conflicts of interest are listed in 'Disclosures: Standards of Medical Care in Diabetes\u20142021' (https://doi.org/10.2337/dc21-SPPC). The ADA funds development of the Standards of Care out of its general revenues and does not use industry support for this purpose. NOTE: The disclosed conflicts of interest was not found at the suggested URL</div>", "status": "generated"}, "entry": [{"type": "ArtifactAssessment", "reference": "ArtifactAssessment/179515"}], "title": "Competing Interests Summary"}, {"code": {"text": "researchConsiderationsSummary", "coding": [{"code": "research-considerations", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Research Considerations"}]}, "title": "Research Priorities Summary", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}]}, {"code": {"coding": [{"code": "methods", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Methods"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>", "status": "empty"}, "title": "Methods Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</div>", "status": "additional"}, "entry": [{"type": "ArtifactAssessment", "reference": "ArtifactAssessment/179515"}], "title": "Evidence"}, {"code": {"coding": [{"code": "discussion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Discussion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>", "status": "empty"}, "title": "Discussion", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "references", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "References"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>", "status": "empty"}, "title": "References Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "competing-interests", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Competing Interests"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>", "status": "empty"}, "title": "Competing Interests Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "acknowledgements", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Acknowledgements"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>", "status": "empty"}, "title": "Acknowledgements Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "appendices", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Appendices"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>", "status": "empty"}, "title": "Appendices Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}]}